The U.S. sucralfate market comprises oral suspension and tablet formulations which are primarily used for the treatment of gastric ulcers. Sucralfate exhibits protective effects on the gastrointestinal lining, preventing damage from gastric acid and stomach enzymes. It acts by forming an aluminum complex that adheres to epithelial surfaces to resist gastric acid erosion. The growing prevalence of gastric ulcers and peptic ulcers due to increasing risk factors such as smoking, alcohol consumption and stress have driven the demand for sucralfate formulations.
The Global U.S. Sucralfate Market Demand is estimated to be valued at US$ 70.05 Mn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the U.S. sucralfate market are Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Johnson & Johnson, Abbott Laboratories, Eli Lilly and Company, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Mylan N.V. and Allergan plc.
The growing demand for gastric ulcer treatment therapies in the United States is driven by increasing risk factors like smoking, diet and stress levels amongst the population. Sucralfate formulations are preferred due to their superior tolerability and minor side effects as compared to histamine H2 receptor antagonists and proton pump inhibitors.
The sucralfate market players are focusing on strategic acquisitions and partnerships with regional pharmaceutical companies to expand their presence globally. For instance, in 2022, Mylan N.V. announced the acquisition of Viatris Inc.’s biosimilar and complex injectables business globally, strengthening their presence in complex generics.
Market drivers
The key driver for the U.S. sucralfate market growth is the rising geriatric population which is more prone to develop gastric ulcers. As per the United States Census Bureau, Americans over 65 years of age are projected to outnumber children for the first time in history by 2030. The weakening of gastrointestinal lining and decreased mucus secretion in older adults increases their risk of gastric inflammation. Hence, sucralfate continues to be the preferred treatment option due to its excellent gastric mucosa protecting abilities and minimal drug-drug interactions.
Impact of Geopolitical Situation on U.S. Sucralfate Market Growth
The current geopolitical uncertainties and conflicts are negatively impacting the growth of the U.S. sucralfate market. The ongoing trade wars between the U.S. and China have disrupted supply chains and increased raw material costs. Restrictions on international trade and exports have made key sucralfate drug ingredients and finished products more expensive. This is posing challenges for drug manufacturers to maintain competitive prices. Moreover, political tensions and economic sanctions on some countries are limiting scope for expanding operations or entering new international markets.
The uncertain global economic environment due to Covid-19 pandemic aftermath has weakened consumer spending power and decreased healthcare budgets in the U.S. Reduction in discretionary healthcare expenditures is restricting market potential. Additionally, workforce shortages and delays in approvals/trials due to staffing issues in the pharmaceutical industry are slowing new product launches. Manufacturers need to focus on cost control, local sourcing and developing innovative pricing strategies to tackle economic headwinds. Diversifying supply networks can help reduce geopolitical risks for long term growth.
Regional Concentration of U.S. Sucralfate Market
Currently, the Northeast region accounts for the largest share of the U.S. sucralfate market in terms of value. This is attributed to high population density, strong healthcare infrastructure and greater prevalence of gastric ulcers in states like New York and New Jersey. The growing geriatric demographic that is more prone to gastric issues is driving market growth. Furthermore, many headquarters of leading pharmaceutical manufacturers are located in this region, improving accessibility of sucralfate drugs.
Fastest Growing Region in U.S. Sucralfate Market
The Southern region, primarily states like Texas, Florida and North Carolina, is poised to be the fastest growing region for the U.S. sucralfate market during the forecast period. This is due to rapidly expanding population, healthcare spending, and number of hospitals/clinics in these states. Increasing focus on specialty care centers treating gastrointestinal disorders is also boosting market revenues. Moreover, higher research and life sciences investments are encouraging clinical research and trials, aiding new product launches.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it